Cargando…
SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC
Non-small-cell lung cancer (NSCLC) is the predominant form of lung cancer, and it is regulated by a complex signal transduction network. Single-agent targeted therapy often results in acquired resistance, which leads to treatment failure. In this study, we demonstrated that a combination of the kina...
Autores principales: | Yuan, Man, Xu, Lin-feng, Zhang, Juan, Kong, Si-yuan, Wu, Man, Lao, Yuan-zhi, Zhou, Hua, Zhang, Li, Xu, Hongxi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689998/ https://www.ncbi.nlm.nih.gov/pubmed/31428570 http://dx.doi.org/10.3389/fonc.2019.00586 |
Ejemplares similares
-
High diagnostic value of miRNAs for NSCLC: quantitative analysis for both single and combined miRNAs in lung cancer
por: Yi, Minhan, et al.
Publicado: (2021) -
Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review
por: Wang, Qian, et al.
Publicado: (2022) -
Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016) -
ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019) -
m(6)A regulators featured by tumor immune microenvironment landscapes and correlated with immunotherapy in non-small cell lung cancer (NSCLC)
por: Yuan, Baowen, et al.
Publicado: (2022)